Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

“As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Andrew F. Berdel, Julian Ronnacker, Daniela V. Wenge, Lina Kolloch, Philipp Berning, Linus Angenendt, Tobias Brix, Annette Westermann, Klaus Wethmar, Torsten Kessler, Andrea Kerkhoff, Rolf M. Mesters, Christian Reicherts, Jan-Henrik Mikesch, Wolfgang E. Berdel, Georg Lenz, Christoph Schliemann, Matthias Stelljes

Blood (2024) 144 (Supplement 1): 4242.

https://doi.org/10.1182/blood-2024-193666

Published: 2024

Journal Articles

A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse

Blood (2021) 138 (Supplement 1): 2345.

https://doi.org/10.1182/blood-2021-145859

Published: 2021

Journal Articles

Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL)

Daniela V. Wenge, Klaus Wethmar, Corinna Klar, Hedwig Kolve, Tim Sauer, Linus Angenendt, Georg Evers, Simon Call, Andrea Kerkhoff, Cyrus Khandanpour, Torsten Kessler, Rolf M. Mesters, Christoph Schliemann, Jan-Henrik Mikesch, Christian Reicherts, Monika Brüggemann, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes

Blood (2021) 138 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2021-146459

Published: 2021

Journal Articles

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Torsten Kessler, MD, Steffen Koschmieder, MD, Christoph Schliemann, MD, Martina Crysandt, Jan-Henrik Mikesch, MD, Matthias Stelljes, MD, Linus Angenendt, Georg Lenz, Anna Kirsch, Kerstin Vehring, Hartmann Wolfgang, Eva Wardelmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, MD, Carsten Mueller-Tidow, Wolfgang E. Berdel, MD

Blood (2018) 132 (Supplement 1): 5176.

https://doi.org/10.1182/blood-2018-99-118095

Published: 2018

Journal Articles

Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation

Christoph Schliemann, MD, Katrin Gutbrodt, PhD, Andrea Kerkhoff, MD, Michele Pohlen, MD, Stefanie Wiebe, MD, Gerda Silling, MD, Linus Angenendt, Torsten Kessler, MD, Rolf M Mesters, MD, Leonardo Giovannoni, PhD, Michael Schäfers, MD, Bianca Altvater, PhD, Claudia Rössig, MD, Inga Grünewald, MD, Eva Wardelmann, MD, Gabriele Köhler, MD, Dario Neri, PhD, Matthias Stelljes, MD, Wolfgang E Berdel, MD

Blood (2014) 124 (21): 980.

https://doi.org/10.1182/blood.V124.21.980.980

Published: 2014

Journal Articles

Targeting Interleukin-2 to the Neovasculature Potentiates Rituximab‘s Activity Against Mantle Cell Lymphoma in Mice

Christoph Schliemann, MD, Niklas Börschel, Christian Schwöppe, PhD, Rüdiger Liersch, MD, Torsten Kessler, MD, Martin Dreyling, Wolfram Klapper, MD, Hans D. Menssen, MD, Dario Neri, PhD, Wolfgang E. Berdel, MD, Rolf M. Mesters, MD

Blood (2012) 120 (21): 3716.

https://doi.org/10.1182/blood.V120.21.3716.3716

Published: 2012

Journal Articles

Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients

Ruediger Liersch, Joachim Gerss, Christoph Schliemann, Michael Bayer, Christian Schwöppe, Christoph Biermann, Iris Appelmann, Torsten Kessler, Bob Löwenberg, Thomas Büchner, Wolfgang Hiddemann, Carsten Müller-Tidow, Wolfgang E. Berdel, Rolf Mesters

Blood (2012) 119 (22): 5215–5220.

https://doi.org/10.1182/blood-2011-11-389692

Published: 2012

Includes: Supplemental data

Journal Articles

Differential Activity of Pazopanib and Imatinib Against PDGFRA-Related MPN and AML

Steffen Koschmieder, MD, Mirle Schemionek, PhD, Christian Elling, PhD, Utz Krug, MD, Torsten Kessler, MD, Wolfgang E. Berdel, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 5153.

https://doi.org/10.1182/blood.V118.21.5153.5153

Published: 2011

Journal Articles

Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C Plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid Leukemia

Uta Brunnberg, Michael Mohr, Richard Noppeney, Heinz A. Duerk, Maria Cristina Sauerland, Carsten Müller-Tidow, Utz O Krug, Steffen Koschmieder, Torsten Kessler, Rolf M. Mesters, Christiane Schulz, Thomas Buchner, Gerhard Ehninger, Ulrich Dührsen, Hubert Serve, Wolfgang E. Berdel

Blood (2010) 116 (21): 335.

https://doi.org/10.1182/blood.V116.21.335.335

Published: 2010

Journal Articles

Targeting Tissue Factor to Tumor Vessels. Experimental Results and First-in-Man Experience.

Wolfgang E Berdel, MD, Torsten Kessler, MD, Christian Schwöppe, PhD, Ruediger Liersch, MD, Torsten Persigehl, MD, Christoph Bremer, MD, Christoph Schliemann, MD, Rolf Mesters, MD

Blood (2009) 114 (22): 469.

https://doi.org/10.1182/blood.V114.22.469.469

Published: 2009

Journal Articles

Expression of Osteopontin in the Bone Marrow of Patients with Acute Myeloid Leukemia.

Ruediger Liersch, MD, Michael Bayer, Christoph Biermann, Iris Appelmann, Christoph Schliemann, MD, Christian Schwoeppe, Torsten Kessler, MD, Carsten Mueller-Tidow, MD, Wolfgang Berdel, Rolf Mesters

Blood (2009) 114 (22): 4694.

https://doi.org/10.1182/blood.V114.22.4694.4694

Published: 2009

Journal Articles

Infarction of tumor vessels by NGR-peptide–directed targeting of tissue factor: experimental results and first-in-man experience

Ralf Bieker, Torsten Kessler, Christian Schwöppe, Teresa Padró, Thorsten Persigehl, Christoph Bremer, Johannes Dreischalück, Astrid Kolkmeyer, Walter Heindel, Rolf M. Mesters, Wolfgang E. Berdel

Blood (2009) 113 (20): 5019–5027.

https://doi.org/10.1182/blood-2008-04-150318

Published: 2009

Journal Articles

Expression of Angiopoietins and Their Receptor Tie2 in the Bone Marrow of Patients with Acute Myeloid Leukemia.

Christoph Schliemann, MD, Ralf Bieker, MD, Teresa Padro, MD, Torsten Kessler, MD, Heike Hintelmann, Thomas Buchner, MD, Wolfgang E. Berdel, MD, Rolf M. Mesters, MD

Blood (2006) 108 (11): 1894.

https://doi.org/10.1182/blood.V108.11.1894.1894

Published: 2006

Journal Articles

Inhibition of Tumor Growth by RGD Peptide Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature.

Torsten Kessler, MD, Ralf Bieker, MD, Teresa Padro, PhD, Federico Herrera, MD, Sandra Ruiz, MD, Hubert Serve, MD, Micheal Kreuter, MD, Wolfgang E. Berdel, MD, Rolf M. Mesters, MD

Blood (2004) 104 (11): 1934.

https://doi.org/10.1182/blood.V104.11.1934.1934

Published: 2004

Journal Articles

Efficacy and safety of thalidomide in patients with acute myeloid leukemia

Martin B. Steins, Teresa Padró, Ralf Bieker, Sandra Ruiz, Martin Kropff, Joachim Kienast, Torsten Kessler, Thomas Buechner, Wolfgang E. Berdel, Rolf M. Mesters

Blood (2002) 99 (3): 834–839.

https://doi.org/10.1182/blood.V99.3.834

Published: 2002

NARROW

“As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse

Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL)

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation

Targeting Interleukin-2 to the Neovasculature Potentiates Rituximab‘s Activity Against Mantle Cell Lymphoma in Mice

Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients

Differential Activity of Pazopanib and Imatinib Against PDGFRA-Related MPN and AML

Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C Plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid Leukemia

Targeting Tissue Factor to Tumor Vessels. Experimental Results and First-in-Man Experience.

Expression of Osteopontin in the Bone Marrow of Patients with Acute Myeloid Leukemia.

Infarction of tumor vessels by NGR-peptide–directed targeting of tissue factor: experimental results and first-in-man experience

Expression of Angiopoietins and Their Receptor Tie2 in the Bone Marrow of Patients with Acute Myeloid Leukemia.

Inhibition of Tumor Growth by RGD Peptide Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature.

Efficacy and safety of thalidomide in patients with acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only